EU HE EUROATOM - SECURE Strengthening the European chain of supply for next generation medical radionuclides
|
Programme |
EURATOM2027 |
|
Call for proposal |
|
|
Funding scheme |
EURATOM-RIA |
|
Consortium |
17 participants |
|
Start date |
1st october 2022 |
|
Duration |
36 months |
Radium-223 is a radioactive isotope – radionuclide – used to treat metastatic cancer. Other radionuclides show promise and could meet future demand, but there are several major challenges to be faced before becoming available.
To address these, the EU-funded SECURE project will identify and use existing resources for new radionuclides, especially alpha- and beta-emitting isotopes. It aims to remove crucial barriers to sustainable production and provide guidance and recommendations for fully exploiting alpha and beta particle therapy. In addition, the project will deliver key lessons learnt to deal with problems in upscaling and sustainably producing isotopes.
Link: https://cordis.europa.eu/project/id/101061230
